Iron deficiency anaemia (IDA) is defined by subnormal haemoglobin levels that prevent the effective transport and utilisation of oxygen. Because iron is the functional component of haemoglobin, iron deficiency occurs in most cases in connection with, or even before, the onset of anaemia. IDA is a common health concern in the developed world, occurring in 2-5% of adult men and post-menopausal women. It occurs when the amount of iron being absorbed by the body is less than that being lost. The three predominant reasons for IDA occurring in people are systemic inflammation, blood loss and malabsorption.1, As such IDA is commonly seen in people with inflammatory bowel disease, chronic heart failure, chronic kidney disease, rheumatoid arthritis, chronic obstructive pulmonary disease and some malignancies.2,
Vifor Pharma, as a leading company in iron replacement therapy, concentrates its activities on the following strategic therapeutic areas: haemodialysis, chronic kidney disease, cardiology, obstetrics / gynaecology, menometrorrhagia / heavy menstrual bleeding, gastroenterology and patient blood management.
1. Goddard A, James M, McIntyre A and Scott B (2011) ‘Guidelines for the management of iron deficiency anaemia’, Gut 60, 1309-1316
2. Huang J and Means R (2008) ‘The frequency and significance of iron-deficiency anemia in patients with selected concurrent illness’, The Internet Journal of Internal Medicine 8, 1
The Old Stables, Bagshot Park, Bagshot
Surrey-UK GU19 5PJ